MOTS-c: The Exercise Peptide You’re Not Making Enough Of
The Peptide Truth Files — Part 3 of 4
This is the part of the series where we leave Tier 1 evidence and enter genuinely exciting emerging science. I want to be clear about that upfront.
MOTS-c does not have Phase 3 human trial data. There are no published interventional studies in PCOS women. What it has is: a mechanistically coherent biological story, solid mouse data, human associational data specifically in PCOS, and a plausible therapeutic rationale that I believe warrants serious clinical attention.
That is different from the BPC-157 conversation (Part 4). The difference matters.
What Is MOTS-c?
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. It’s a 16-amino acid peptide encoded not in nuclear DNA, but within the mitochondrial genome itself — specifically inside the 12S ribosomal RNA gene.
It was discovered in 2015 by Chang Lee’s group at USC, published in Cell Metabolism. It was the second mitochondria-derived peptide (MDP) identified after humanin, and its discovery fundamentally changed how we understand mitochondrial biology. Mitochondria, it turns out, are not just energy factories — they are endocrine organs, secreting peptide signals that regulate whole-body physiology.
MOTS-c is conserved across 14 species with remarkable evolutionary pressure — suggesting it does something important enough that natural selection has preserved it across hundreds of millions of years.
MOTS-c is what your mitochondria secrete when they want your muscles to use glucose more efficiently. PCOS women aren’t getting that signal. That is not a small thing.
What MOTS-c Actually Does
MOTS-c’s primary target organ is skeletal muscle. Its cellular mechanism:
Inhibits the folate cycle and de novo purine biosynthesis in skeletal muscle cells
This inhibition leads to accumulation of AICAR (an AMP analog)
AICAR activates AMPK — the master metabolic switch that improves insulin sensitivity, promotes glucose uptake, and activates mitochondrial biogenesis
This is the same pathway activated by metformin and by aerobic exercise — which is why MOTS-c has been called an “exercise mimetic”
Beyond skeletal muscle, MOTS-c:
Reduces adipogenesis and promotes fat oxidation
Has anti-inflammatory effects — reduces NF-κB signaling and inflammatory cytokine production
Supports mitochondrial quality control (mitophagy)
In aging models, extends lifespan and healthspan in mice
The PCOS Connection: What the Human Data Shows
Study 1 — Scientific Reports, February 2026: 40 women with PCOS vs. 40 age- and BMI-matched healthy controls. Serum MOTS-c measured by ELISA. Skeletal muscle MOTS-c expression assessed in vastus lateralis biopsies.
Circulating MOTS-c concentrations were significantly lower in PCOS women
Skeletal muscle MOTS-c expression was also significantly lower in PCOS women
The skeletal muscle MOTS-c deficit was associated with insulin resistance, inflammation markers, and hormonal imbalance
This is the first study to demonstrate tissue-level MOTS-c deficiency in PCOS — not just a circulating biomarker difference, but reduced expression in the primary target organ.
Study 2 — Clinical Endocrinology, 2019: Established that insulin attenuates MOTS-c responses in both PCOS and healthy subjects. The hyperinsulinemia in PCOS may be suppressing the body’s own MOTS-c production. This is a double hit: PCOS drives high insulin, high insulin suppresses MOTS-c, low MOTS-c worsens insulin resistance.
The Humanin Parallel: Serum humanin levels were significantly lower in PCOS women (474.9 pg/mL vs. 672.3 pg/mL in controls, p<0.001), with negative correlations to testosterone, LDL, triglycerides, and 120-minute insulin during OGTT. Two mitochondrial peptides, both reduced in PCOS. The pattern is not coincidental.
THE BIOLOGICAL MODEL: PCOS creates hyperinsulinemia → hyperinsulinemia suppresses MOTS-c and humanin → loss of these endogenous signals worsens mitochondrial function and insulin signaling → further insulin resistance. A vicious cycle running in the mitochondrion, in parallel to the insulin-androgen loop.
Why Exercise Works Less Well in PCOS — And What to Do About It
Acute aerobic exercise increases circulating MOTS-c in humans. But studies in PCOS women specifically show blunted MOTS-c response to exercise compared to healthy controls. The capacity to generate and respond to this mitochondrial signal may be impaired in PCOS.
Additionally: sixteen weeks of combined endurance and resistance exercise was required to produce meaningful MOTS-c elevation in one study. Two weeks of cycling and eight weeks of endurance exercise in PCOS women did not significantly alter MOTS-c or humanin levels.
Implications for exercise prescription:
Intensity and duration matter — not just “move more”
Resistance training combined with aerobic training
Progressive overload
Minimum 12–16 weeks for meaningful mitochondrial adaptation
The goal is mitochondrial adaptation, not calorie deficit. Prescribe accordingly.
Could MOTS-c Become a Therapeutic? Honest Accounting
In February 2026, MOTS-c was reclassified to FDA Category 1 — meaning it can be legally compounded by a licensed pharmacy with a physician’s prescription. This is not FDA approval. This is a regulatory pathway.
What the evidence base shows:
Animal data: robust. Prevents diet-induced and age-related insulin resistance. Mechanism well-characterized. Results replicate.
Human associational data: compelling, specific to PCOS, published 2024–2026.
What the evidence base does NOT show:
No interventional human trials in PCOS
No established human pharmacokinetics — no oral bioavailability data, no dosing guidance
No formal safety trials in women, no periconception data, no long-term safety data
This leaves us exactly where rigorous clinical research should begin. If I were designing that trial: a 24-week RCT in PCOS women, HOMA-IR as primary endpoint, testosterone and ovulation rate as secondary endpoints, with continuous ketone monitoring to track metabolic flexibility as a real-time biomarker of mitochondrial fuel utilization.
That’s where the field needs to go. That’s not where it is yet.
What You Can Do Now
Structured progressive exercise — specific prescriptions, intensity targets, minimum 12–16 weeks
Myo-inositol at the 40:1 ratio — reduces hyperinsulinemia, which directly suppresses MOTS-c
CoQ10 and alpha-lipoic acid — support the mitochondrial environment; established safety profiles
Continuous ketone monitoring — real-time proxy for mitochondrial fuel utilization and metabolic flexibility
Gut-targeted nutrition — dietary fiber, resistant starch, fermented foods (the butyrate → PGC-1α → mitochondrial biogenesis pathway)
Key Citations
Lee C et al. (2015). MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3): 443–454.
Reduced serum and skeletal muscle MOTS-c in PCOS associated with mitochondrial dysfunction. Scientific Reports, February 2026.
Assessment of mitochondrial peptide humanin in PCOS. J Endocrinol Invest, 2025.
Lipids and insulin regulate mitochondrial-derived peptide MOTS-c in PCOS and healthy subjects. Clin Endocrinol, 2019.
Reynolds JC et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator. Nature Communications.
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.